{"id":"W3030967068","doi":"10.1200/jco.2020.38.15_suppl.tps3656","title":"An open-label, first-in-human, phase I trial of the safety and efficacy of daily PCLX-001.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; Spinal Cord Injury BC","funders":"","keywords":"Tolerability; Medicine; Pharmacokinetics; In vivo; Lymphoma; Cancer; Internal medicine; Oncology; Pharmacology; Cancer research; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002165735,0.0001155486,0.001745429,0.00004766219,0.00003514611,0.000004616389,0.0004589164,0.0002076396,0.0001359066],"category_scores_gemma":[0.003299097,0.00007094113,0.0001370304,0.0001718455,0.0004629669,0.0001558533,0.00014008,0.0007934737,8.399139e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005963399,"about_ca_system_score_gemma":0.0007413335,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002011634,"about_ca_topic_score_gemma":0.00003902148,"domain_scores_codex":[0.9962306,0.0004777524,0.002675163,0.0001782806,0.0002883763,0.0001498459],"domain_scores_gemma":[0.994958,0.001951749,0.002291596,0.0002550055,0.0002541127,0.0002895803],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.663708,0.01588496,0.004999351,0.000079212,0.0003704158,0.0001434549,0.0006464708,0.00006218008,0.005795297,0.0003369441,0.0004350685,0.3075386],"study_design_scores_gemma":[0.7376835,0.1024339,0.05425392,0.0002287457,0.0003581529,0.0001016396,0.0001797092,0.0001343567,0.0003925374,0.0004218193,0.1037082,0.0001035873],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9790999,0.0003620966,0.0001005421,0.0188251,0.0005257128,0.0005303639,0.00001116348,0.00000348272,0.0005416881],"genre_scores_gemma":[0.9947635,0.0003066024,0.001670313,0.002236519,0.0009677971,0.000001851816,0.000001641813,0.00001548311,0.00003630267],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.307435,"threshold_uncertainty_score":0.3949565,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1866808923102349,"score_gpt":0.5238295491597984,"score_spread":0.3371486568495635,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}